MENLO PARK, Calif., April 30, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), a Wheat Ridge, CO-based company developing an advanced mapping system to guide the treatment of atrial fibrillation (AFib), today announced the closing of a $21.5 million Series A financing round led by Ajax Health. Ablacon’s novel algorithm uses artificial intelligence (AI) to analyze and visualize […]
Tag: AFib
Alchem International Solves Stability Problems in Micronized Digoxin and Files Patent for New Manufacturing Process
GENEVA, April 25, 2019 / PRNewswire / – Alchem International Private Limited (“Alchem”), a privately held pharmaceutical company specializing in the production of plant-derived active pharmaceutical ingredients (APIs), today announced the launch of its platform owner of micronized digoxin. The Alchem molecule is the only micronized digoxin available worldwide that […]
Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Stage Renal Disease and Atrial Fibrillation
JACKSONVILLE, Fla. and IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis and cardiac rhythm control, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin […]
CardioFocus Initiates Persistent Atrial Fibrillation Study With The Breakthrough HeartLight® X3 System
MARLBOROUGH, Mass., March 5, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the first enrollments in a clinical study evaluating use of the HeartLight X3 System in an early persistent AFib patient population. The 60 patient, prospective study will be led […]
AtriCure Announces The Society of Thoracic Surgeons Has Endorsed the Company’s Advanced Ablation Courses in the United States
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (STS) has endorsed its Advanced Ablation course for both physicians and fellows. The course provides surgeons and other medical professionals with […]
Kardium Announces New Financing to Commercialize the Globe System for the Treatment of Atrial Fibrillation
VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, announced today that it has raised an undisclosed amount in a new financing round. The financing was led by funds and accounts advised by T. Rowe Price Associates, Inc., and included participation from […]
Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention
New Brunswick, NJ, January 17, 2019 — Johnson & Johnson (NYSE: JNJ) today announced that Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a research study in collaboration with Apple Inc. to investigate whether a new heart health program using an app from Johnson […]
Conformal Medical Announces $9 million Series B Financing
NASHUA, N.H., Dec. 3, 2018 /PRNewswire/ — Conformal Medical, Inc., developer of the Conformal Left Atrial Appendage Seal for LAA occlusion, has secured $9 million in Series B funding. Conformal is developing proprietary seal technology for the prevention of stroke in patients with atrial fibrillation (AFib). Over five million people in the United States have AFib, […]
AtriCure to Participate in Upcoming Investor Conferences
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel 2018 Healthcare Conference in New York City on Wednesday, […]
ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
WESTMINSTER, Colo., Sept. 18, 2018 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA). The request is part of the […]



